[ biotech news ] Schaeffer's S&P 500 Index Hot Stocks Features Brunswick, MedImmune, Merck, Delph

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Schaeffer's S&P 500 Index Hot Stocks Features Brunswick, MedImmune,
Merck, Delphi, and Murphy Oil

Aug. 29, 2005
Among the stocks featured in the August 29 edition of Schaeffer's
S&P 500 Index Hot Stocks are Brunswick (NYSE:BC), MedImmune
(NASDAQ:MEDI), Merck (NYSE:MRK), Delphi (NYSE:DPH), and Murphy Oil
(NYSE:MUR). Schaeffer's S&P 500 Index Hot Stocks is just one of the
many free market commentaries written every day at
www.SchaeffersResearch.com - the home of Bernie Schaeffer and
Schaeffer's Investment Research.

Schaeffer's S&P 500 Index Hot Stocks for Monday, August 29, 2005:

A daily feature available on SchaeffersResearch.com is the "SPX Hot
Stocks" column. Each afternoon, we will provide a list of the day's
top-20 performing stocks in the S&P 500 Index (SPX - 1,210.76) as
well as the bottom-20 names. Featured along with this table will be
news that is moving some of the securities.

NOTE: Stocks trading under $5 per share have been eliminated from
this listing of the top-20 and bottom-20 performing stocks.

Despite oil ascending to record heights in today's trading action,
the SPX has been able to advance 0.47 percent. Overnight, crude
futures hit $70.80; however, last check shows that black gold is
trading 87 cents higher on the day at $67 per barrel. The market
action seems to be defying what investors expect, with some stating
that stocks "should be trading a lot lower." Currently, we only have
short-term estimates about the damage Katrina has caused, some
investors believe that the market will suffer as the sky clears and
we can get a handle on the damage.

Atop the hot stocks list this afternoon is Allegheny Technologies
(ATI) with a gain of more than four percent on no discernable news,
and seeing how this is a news driven article, I will skip over
PerkinElmer (PKI) and move on to Brunswick (NYSE:BC). The Illinois-
based producer of all things leisure, except for those hideous
polyester suits, received an upgrade from "hold" to "buy" from the
kind-hearted analysts at Citigroup. BC produces pleasure boats,
bowling and billiard products, and fitness equipment.

Moving further down the list, I see a gain of more than two percent
for biotech equity, MedImmune (NASDAQ:MEDI). MEDI licensed the
worldwide rights from GlaxoSmithKline (GSK) to develop
antistaphylococcal monoclonal antibodies in exchange for an upfront
payment. Possible milestone fees and future royalties are also
included in the deal. MEDI has also taken over future milestone and
royalty payments to Biosynexus, from whom GSK originally licensed
the BSYX-A110 antibody, which will help the company expand into the
development of monoclonal antibodies in pediatrics.

I had to dig all the way down to the final advancer on the day to
find any kind of news to report, and it is actually good news for
shaken pharmaceutical firm Merck (NYSE: MRK). This afternoon, the
purveyor of pills to cure your ills advanced thanks mainly to
Hurricane Katrina. The first federal case filed over its recalled
drug Vioxx was set to go to trial in New Orleans in November.
Today's storm may serve to delay this case as the citizens of the
city clean up after Hurricane Katrina.

On Friday, Delphi (NYSE:DPH) led a group of auto parts makers lower,
and its decline hasn't stopped today. Tomorrow, DPH's former parent,
General Motors (GM), will discuss at its analyst meeting whether or
not it will help lend some financial relief to its struggling
supplier. This news follows a week where the dean of the driveshaft
saw itself upgraded to "neutral" from "underperform" at Baird.
Unfortunately, Friday's fall included Dana (DCN), which seems to be
tethered to DPH again today, as both equities have lost more than
four percent.

Hurricane Katrina has boosted oil and oil-related stocks, but one
oil stock that is not advancing thanks to the weather is Murphy Oil
(NYSE:MUR). Forecasters say that Katrina hit land at Plaquemines
Parish, Louisiana, which is near MUR's refinery at Meraux,
Louisiana. The Meraux facility usually pumps out 120,000 barrels of
black gold per day.

About an hour ago, AIR Worldwide estimated that Hurricane Katrina
could cost the insurance industry between $12 billion and $26
billion. If the cleanup carries that hefty of a price tag, it will
be one of the two worst natural catastrophes in U.S. history. This
news has not helped the insurance industry, proven by a drop of
nearly two percent from Allstate (ALL).

Take advantage of the timely Schaeffer commentaries by signing up
for their free e-newsletters -- Opening View, Market Recap and
Monday Morning Outlook. Click here to have the Schaeffer's
commentaries delivered to you free via email every day.

About Schaeffer's Investment Research (www.SchaeffersResearch.com)

Schaeffer's Investment Research, founded by Bernie Schaeffer in
1981, is a financial information and trading resources company. It
publishes Bernie Schaeffer's Option Advisor, the nation's leading
options subscription newsletter. The firm's contrarian approach
focuses on stocks with technical and fundamental trends that run
counter to investor expectations.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Novel lipoplex nanoparticle to be used in 1st human trial treating advanced soli

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Novel lipoplex nanoparticle to be used in 1st human trial treating
advanced solid cancer

The first clinical trial of a biologic nanoparticle designed to give
back to cancer patients the tumor-busting gene they have lost is
expected to start in September at Georgetown University Medical
Center.

e phase I clinical study will enroll 20 patients with advanced solid
cancers ( including most common tumor types ), and is the
culmination of more than a decade of work by a team of researchers
led by Professor Esther H. Chang, Ph.D. at the Lombardi
Comprehensive Cancer Center.

Their research has led to development of a tiny structure --
measuring a millionth of an inch across -- that resembles a virus
particle that can penetrate deeply into the tumor and move
efficiently into cells. The device is a "liposome" -- a microscopic
globule made of lipids -- that is spiked on the outside with
antibody molecules that will seek out, bind to, and then enter
cancer cells including metastases wherever they hide in the body.
These molecules bind to the receptor for transferrin that is present
in high numbers on cancer cells.

Once inside, the nanoparticle, which the researchers call
a "immunolipoplex," will deliver its payload -- the p53 gene whose
protein helps to signal cells to self-destruct when they have the
kind of genetic damage characterized by cancer and by cancer
therapies.

More than half of all cancer patients have cancer cells that have
lost normal functioning of the p53 gene, so-called "guardian of the
genome," and the Georgetown researchers believe that restoring the
gene will improve the tumor-killing ability of traditional
treatments.

"We are excited about the promise this nanoparticle has shown in
animal tumor models, and are anxious to offer it to patients," said
Chang, Professor in the Department of Oncology and Co-director of
the Molecular Targets & Developmental Therapeutics Program at
Georgetown.

The federal Food and Drug Administration granted approval for the
trial to begin in late July. The work is being sponsored by grants
from the National Institutes of Health and private foundations.
Additional support comes from SynerGene Therapeutics, a biotech
research firm with which Chang collaborates.

John Marshall, M.D., Director of Developmental Therapeutics and GI
Oncology at Georgetown, will serve as the trial's principal
investigator.

The researchers believe that immunolipoplex represents an advance
over the viral "vectors" that have been used to deliver gene
therapy, because these liposomes do not produce the kinds of
immunologic response seen when disabled viruses are used to carry
the payload. They also say that the nanoparticle is of a small
uniform size and consistency, and has been proven to work in animals
bearing tumor.

In preclinical research, Chang and long-term research colleague
Kathleen Pirollo, Ph.D. have found that these nanoparticles
substantially improve the tumor-fighting power of both chemotherapy
and radiation therapy. These agents work synergistically with
traditional therapies because the newly restored p53 protein helps
push cancer cells that are now damaged to self-destruct.

"We believe this approach will make it difficult for the cancer
cells to become resistant to therapy," Chang said. "As a result,
cancers treated with these liposomal formulations should be less
likely to recur after therapy is complete."

For example, use of these p53-loaded liposomes in combination with
radiation therapy eliminated prostate and head and neck tumors in
mice, which then survived cancer-free for more than 200 days --
until they all died of old age. Similar promising results were seen
when the nanoparticles were combined with chemotherapy to treat
animal models of melanoma and aggressive breast cancer.

Among the solid tumors approved for testing in the clinical trial
are head and neck, prostate, pancreatic, breast, bladder, colon,
cervical, brain, melanoma, liver and lung cancers.

Laura Cavender
lsc6 @ georgetown.edu
202-687-5100
Georgetown University Medical Center
gumc.georgetown.edu

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] SciFinder 2006 launches powerful new substance search capablities

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

SciFinder 2006 launches powerful new substance search capablities

Washington, D.C., August 28, 2005 - Building upon a decade of
innovation, the new SciFinder 2006 advances its reputation as an
essential information tool and part of the process of chemical and
pharmaceutical research. For the first time, scientists exploring
the CAS Registry of 26 million organic and inorganic chemical
substances can retrieve "similar substances" to foster new ideas and
directions in drug discovery and other fields of scientific
inquiry. "Similarity Searching" is only one of several new features
adding new power and depth to SciFinder this year. CAS, a division
of the American Chemical Society, launched SciFinder 2006 and
SciFinder Scholar 2006 this week at the American Chemical Society
meeting in Washington, D.C.

SciFinder provides similarity searching of CAS registry
Washington, D.C., August 28, 2005 - Building upon a decade of
innovation, the new SciFinder 2006 advances its reputation as an
essential information tool and part of the process of chemical and
pharmaceutical research. For the first time, scientists exploring
the CAS Registry of 26 million organic and inorganic chemical
substances can retrieve "similar substances" to foster new ideas and
directions in drug discovery and other fields of scientific
inquiry. "Similarity Searching" is only one of several new features
adding new power and depth to SciFinder this year. CAS, a division
of the American Chemical Society, launched SciFinder 2006 and
SciFinder Scholar 2006 this week at the American Chemical Society
meeting in Washington, D.C.
Nobel Laureate, Dr. K. Barry Sharpless, W. M. Keck Professor of
Chemistry at the Scripps Research Institute, shared his reflections
regarding the significance of SciFinder:

"We were using SciFinder at Scripps even before SciFinder Scholar
was invented," said Dr. Sharpless. "I am a big user and don't see
how any researcher could hope to excel without daily, round-the-
clock access. In the old days, you could be forgiven for not knowing
about a certain paper, but now there is no excuse. The speed and
scope of its search power is amazing, and the answer to 'what aspect
is most helpful for you?' could be as diverse as the users. In my
case, SciFinder enhances my reactivity insights, making it easier
to 'see' those ill-defined boundaries where important new phenomena
are lurking."

New features of SciFinder 2006 include:

Similarity Searching - as a complement to SciFinder substructure
searching, similarity searching permits new options for identifying
substances of interest via precise statistical analysis using the
Tanimoto algorithm;

Structure Query Tools - to identify substances more precisely, new
tools permit drawing a variable attachment point and a repeating
group;

Reaction Searching - finding reaction information has been enriched
with new content and features; these include reaction conditions and
identifying intermediate reactions in a multi-step reaction.
Scientists can also click any substance in the reaction display to
find additional information, including retro-synthetic pathways;

Navigation & Usability - improvements include duplicate detection
and removal for more efficient combined searching of the CAplus and
MEDLINE databases. A new Locate feature permits quick access to
journal and patent documents by entering journal titles, author
names and other partial bibliographic information.
While announcing the release of SciFinder 2006 for Windows, CAS
revealed that a native MAC OS X version of SciFinder will appear in
fourth quarter 2005.

SciFinder was created in 1995 with the vision of providing
scientists easy, point-and-click access to chemical information. The
new intelligent research tool -- a client-server product for the
desktop -- was an immediate hit with scientists, assisting them and
other researchers worldwide with access to the multidisciplinary CAS
databases. Today, tens of thousands of scientists at pharmaceutical,
biotech and chemical companies around the world use SciFinder
regularly to explore research topics, browse scientific journals and
stay up-to-date on recent scientific developments. SciFinder Scholar
was introduced in 1998 to serve the needs of campus-wide searching
in academia and now serves more than 1,000 institutions of higher
learning worldwide.

###
CAS, a division of the American Chemical Society, provides the
world's largest and most current collection of chemical and related
scientific information, including the most authoritative database of
chemical substances, the CAS Registry. CAS combines these databases
with advanced search and analysis technologies to deliver the most
complete and effective digital information environment for
scientific research and discovery, including such products as
SciFinder, SciFinder Scholar, STN, STN Express and STN AnaVist,
among others. The CAS web site is at www.cas.org.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech research center wins $1 million in grants - 2005-08-29
Biotech research center wins $1 million in grants - 2005-08-29

Biotech research center wins $1 million in grants
NMBW Staff
The National Center for Genome Resources (NCGR) announced Monday it has received two grants worth more than $1 million to develop information and search systems for agricultural researchers.


The two grants were both awarded by the Agricultural Research Service, a division of the U.S. Department of Agriculture.

The first grant, totaling $790,000, will be used by the Santa Fe-based NCGR for the continued development of the four-year-old Legume Information System (LIS). LIS is a Web-based information tool that has been used by scientists nationwide to translate model plant species to economically feasible crops, according to the NCGR announcement.

NCGR will continue to work with the Agricultural Research Service on the LIS project.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Business 2.0 :: Magazine Article :: Features :: Tech Giants Court The Genome Crowd
Tech Giants Court The Genome Crowd

Desperate for good news and new markets, leading technology companies look toward red-hot genomics and bioinformatics for salvation.

Business 2.0 :: Magazine Article :: Features :: Tech Giants Court The Genome Crowd



By Carolyn Marshall, May 29, 2001

It's close to midnight in San Francisco and J. Craig Venter, president and chief scientific officer of Celera Genomics, is dancing like a madman. Black tie still tight, Venter mock surfs in rhythm to a blaring oldie by the Beach Boys. The maverick scientist, it seems, is the beau of this $85,000 ball, the first of several champagne-and-caviar events planned worldwide and hosted by Celera's gene team to honor the men and women who made DNA a household word.


Venter is both blamed and credited with triggering a bitter rivalry between the public and private teams racing to decode the Human Genome. The teams delivered final versions of the gene map in February and since then it has been non-stop for Venter and his colleagues: press conferences, seminars, television appearances and, yes, time spent with gene groupies and Nobel wannabes anxious to snag an autograph or pose with Venter for a snapshot.


But behind every larger-than-life celebrity, a phalanx of assistants exist-rarely seen but essential to maintaining the star's celebrity status. In this case, that phalanx is a $50 million supercomputing "server farm" with 600 DNA sequencing machines and 64-bit, 833 MHz AlphaServer systems made by Compaq Computer.


"Celera never would have been able to pull this off without us," crows Ty Rabe, Compaq's director of High Performance Technical Computing Solutions, in Marlboro, Mass.



Biotech News
Biotech News
AZ Entrepreneurs
AZ Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Largest Scientific Conference of Year To-Date on Anti-Aging Medicine Explores Major Breakthroughs in Human Longevity
Largest Scientific Conference of Year To-Date on Anti-Aging Medicine Explores Major Breakthroughs in Human Longevity
American Academy of Anti-Aging Medicine (A4M) welcomes 3,000-plus physicians and scientists to Chicago, as more than 3,000 delegates participated in the world's largest scientific conference to-date on the topics of medical intervention to prevent and treat the diseases and disabilities associated with the biological process of aging.


More than 3,000 delegates participated in the world's largest scientific conference to-date on the topics of medical intervention to prevent and treat the diseases and disabilities associated with the biological process of aging.

These cutting-edge innovative physicians and health practitioners who are involved in improving and extending the human lifespan represented more than 50 nations around the world.

Taking place from Aug. 18-21, the XIII Annual International Congress on Anti-Aging Medicine Summer 2005 Session offered 50 hours of Category 1 AMA/PRA Credits focusing on scientific educational programming in some of the most promising arenas of preventive medicine, including:
- Stem cell therapeutics and regenerative medicine
- Laser surgery, skin resurfacing, fillers, and other facets of aesthetic medicine
- Biomarkers of aging
- Obesity and medical weight management
- Cardiovascular disease prevention and treatment
- Hormone replacement therapy
- Vitamin therapies
- Cognitive testing and maintenance of mental performance

Comments Dr. Ronald Klatz, A4M founder and President: "The faculty of this event consisted of dozens of high-caliber, world-renowned specialists in their respective scientific fields. The level of academic programming at the XIII International Congress on Anti-Aging Medicine remains unparalleled when compared to any other scientific conferences in preventive medicine and/or biotech around the world."

The XIII Annual International Congress on Anti-Aging Medicine's Summer 2005 Session was sponsored by The American Academy of Anti-Aging Medicine (A4M; http://www.worldhealth.net), the academic leader in a worldwide movement in life enhancement and life extension that involves more than 50,000 physicians in 80 countries. The A4M is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues. A4M is a leading world provider of medical education, as its scientific promotion of anti-aging medical technologies will train more than 30,000 physicians via their two dozen separate physician education programs over the next 12 months worldwide. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.

At the XIII Annual International Congress on Anti-Aging Medicine's Summer 2005 Session, a three-hour Panel Discussion shared "New Discoveries and Cutting-Edge Innovations in Medicine and Healthcare from America's Top Medical Journalists/Investigators and Newsletter Publishers." At this panel, key topics included freedoms in healthcare choices and the return to a focus on patient care.

Awards were presented to two distinguished physicians in recognition of their outstanding service to humanity:
- Presentation of the Medical Humanitarian Award by Dr. Robert Goldman, A4M Chairman, to Dr. Henry Heimlich, inventor of the lifesaving Heimlich Maneuver
- Presentation of the Lifetime Education Award by Dr. Robert Goldman, A4M Chairman, to Dr. William Lane, founder of the I.W. Lane College of Integrative Medicine

Today's mature adults control more than $7 trillion in wealth in the United States [Harvard Business Review, March 2004, or 70 percent of all US wealth. Further, they bring in $2 trillion in annual income and account for 50 percent of all discretionary spending." [Associated Press, March 7, 2004. At the co-located Chicago Anti-Aging Exposition, more than 300 corporate booths displayed the latest technologies from the medical and biotech market aimed at improving and/or extending the human lifespan. The United States market for anti-aging products and services exceeds $45.5 billion (2004). Growing at an average annual growth rate of 9.5 percent, this market will reach nearly $72 billion by 2009. [Business Communications Company, Inc., February 2005. Companies with products and services in the $7.7 billion appearance products and services market also were represented.

Remarks Dr. Robert Goldman, A4M Chairman: "This is the largest event of its kind in the world, and very much an interdisciplinary event as the program includes facets from endocrinology, spa medicine, plastic surgery and aesthetic medicine, sports medicine, and other fields of preventive healthcare. The XIII International Congress on Anti-Aging Medicine Winter 2005 Session is anticipated to be double in size  6,000 attendees and 600 corporate booths, representing the most innovative advancements in life enhancement and life extension medical technologies."

The XIII International Congress on Anti-Aging Medicine Winter 2005 Session and co-located Las Vegas Anti-Aging Exposition will take place 9-12 December 2005 at The Paris Hotel in Las Vegas, Nevada USA. For program details and online registration, visit http://www.worldhealth.net/event. For exhibit and sponsorship opportunities, contact the A4M Sales Department at (561) 392-7791 or send fax to (561) 338-1873.

The American Academy of Anti-Aging Medicine, Inc. ("A4M") is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues. A4M believes that the disabilities associated with normal aging are caused by physiological dysfunction which in many cases is ameliorable to medical treatment, such that the human lifespan can be increased, and the quality of one's life enhanced as one grows chronologically older. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan. Anti-Aging Medicine is based on the scientific principles of responsible medical care consistent with those of other healthcare specialties. Although A4M seeks to disseminate information on many types of medical treatments, it does not promote or endorse any specific treatment nor does it sell or endorse any commercial product.

Source: The American Academy of Anti-Aging Medicine (A4M), Chicago, IL




Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Iowans talk biotech with Chinese
Iowans talk biotech with Chinese



Biotechnology will be critical to feeding China’s growing population, said a key government official Aug. 10 at a forum with Iowa farmers in Beijing.

Truth About Trade & Technology - Iowans talk biotech with Chinese


“We need technology, especially biotechnology,” stated Dr. Hong Guang Wang, director general of the National Center for Biotechnology Development, Ministry of Science and Technology for the People’s Republic of China (PRC).

He addressed the Iowa Farm Bureau Federation (IFBF) board of directors at a China-U.S. Applied Biotechnology Forum held Aug. 10-11 in Beijing.

Food is a critical issue for one of the world’s most populous nations. Wang said imports of U.S. corn and soybeans will be needed.

“The United States is the largest producer in the world, so I think we need to work more and more closely together,” stated one of the government’s most influential scientific leaders.

Wang predicted that biotechnology in agriculture will bring a “Green Revolution” over the next 20 to 30 years, one “more powerful than the first revolution.”
“This meeting is quite important to us,” he stated.

Iowa Farm Bureau President Craig Lang succinctly stated the viewpoint of U.S. farmers on biotechnology.

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News



Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech advance in grape controls - BOTRY-Zen
Biotech advance in grape controls


The New Zealand Herald

27.08.05

Dunedin biotechnology company BOTRY-Zen is looking to add another two biological controls to its product suite.

Chief executive John Scandrett told the company's annual meeting that it was evaluating the commercial prospects of two newly developed controls for grape diseases to add to its BOTRY-Zen biological control for the grape-wasting botrytis cinera fungus.

BOTRY-Zen has an agreement with the New Zealand Wine Institute and HortResearch for new products, and a $200,000 grant it has received from the Wine Institute will help with the evaluation.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Worldwide Biotech & Pharmaceutical Obtains the China Patent Golden Medal For Its

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Worldwide Biotech & Pharmaceutical Obtains the China Patent Golden
Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'

Marks the Highest Award Over the Past 10 Years in the Biomedical
Sciences
Industry in China

XI'AN, China, Aug. 25 -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP) (''WWBP'') has
obtained the
China Patent Golden Medal for ''the Intact Hepatitis C Virus (HCV)
and Method
for Culturing HCV in Vitro by Cell Culture.''
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing
HCV in vitro by Cell Culture'' was awarded the Chinese Patent by
China Patent
Bureau on October 23rd, 2002. The patent was then awarded the
prestigious
China Patent Golden Medal (Chinese Patent No. 01124001.6) in the 8th
China
Patent Assessment organized by both General World Intellectual
Property
Organization (WIPO) and the China Patent Office. Importantly, this
patent was
recognized by the World Intellectual Property Organization (WIPO),
issued as
an outstanding Chinese Patented Invention, and was the highest award
issued
for achievements in the biomedical sciences industry over the past
10 years in
China.
''We are highly encouraged with our patent which is recognized
by the WIPO
and it is such a great achievement for the whole company. It's a
great
milestone,'' said WenXia Guo, CEO and President of WWBP, ''the
success of this
patented invention leads our company to a worldwide market, we will
continue
our development and research of new inventions and bring health to
every
customer.''

About World Intellectual Property Organization (WIPO)
The World Intellectual Property Organization (WIPO) is an
international
organization dedicated to promoting the use and protection of works
of the
human spirit. These works -- intellectual property -- are expanding
the
bounds of science and technology and enriching the world of the
arts. Through
its work, WIPO plays an important role in enhancing the quality and
enjoyment
of life, as well as creating real wealth for nations. With
headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United
Nations system of organizations. It administers 23 international
treaties
dealing with different aspects of intellectual property protection.

About Worldwide Biotech & Pharmaceutical Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech
company with top-ranking pharmaceutical R&D abilities, Good
Manufacturing
Practices (GMP) licensed manufacturing facilities and a well-
established
marketing network in China and Southeast Asia. The product range of
WWBP
covers Hepatitis C Virus (HCV) products, diagnostic medicines and
Over-The-Counter (OTC) drugs. WWBP currently possesses 35,940
square meters
of land and 5,359 square meters of GMP standard facilities. With
strong
pharmaceutical R&D abilities especially in the HCV field, WWBP has
been known
as the first biotech company in the world to hold the technology of
culturing
intact HCV in vitro by cell culture.
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is
expected to bring WWBP considerable gross sale revenue each year and
greatly
strengthen the company's R&D on anti-HCV drug screen and HCV human
vaccine.
WWBP had successfully reached two Memoriam of Understanding of Merger
Agreements with pharmaceutical companies in China, all of which have
scalable
production and well-established sales networks, and the acquiring is
expected
to be finished before the end of September 2005. The acquisitions
will
strengthen WWBP's R&D abilities and production scale, as well as
extend its
marketing network throughout China and Southeast Asia. WWBP has
been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.

Safe Harbor
Information in this news release may contain statements about
future
expectations, plans, prospects or performance of Worldwide Biotech &
Pharmaceutical Co. that constitute forward-looking statements for
purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act
of 1995. The words or phrases "can be," "expects," "may
affect," "believed,"
"estimate," "project," and similar words and phrases are intended to
identify
such forward-looking statements. Worldwide Biotech & Pharmaceutical
Co.
cautions you that any forward-looking information provided by or on
behalf of
Worldwide Biotech & Pharmaceutical Co. is not a guarantee of future
performance. None of the information on this website constitutes an
offer to
sell securities or investment advice of any kind, and visitors
should not base
their investment decisions on information contained in this website.
Worldwide
Biotech & Pharmaceutical Co.'s actual results may differ materially
from those
anticipated in such forward-looking statements as a result of various
important factors, some of which are beyond Worldwide Biotech &
Pharmaceutical
Co.'s control. In addition to those discussed in Worldwide Biotech &
Pharmaceutical Co.'s press releases, public filings, and statements
by
Worldwide Biotech & Pharmaceutical Co.'s management, including, but
not
limited to, Worldwide Biotech & Pharmaceutical Co.'s estimate of the
sufficiency of its existing capital resources, Worldwide Biotech &
Pharmaceutical Co.'s ability to raise additional capital to fund
future
operations, Worldwide Biotech & Pharmaceutical Co.'s ability to
repay its
existing indebtedness, the uncertainties involved in estimating
market
opportunities and, in identifying contracts which match Worldwide
Biotech &
Pharmaceutical Co.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such
statements were made. Worldwide Biotech & Pharmaceutical Co. does
not
undertake any obligation to publicly update any forward-looking
statement to
reflect events or circumstances after the date on which any such
statement is
made or to reflect the occurrence of unanticipated events.

SOURCE Worldwide Biotech & Pharmaceutical Company

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php
http://www.mail-archive.com/biotech-news@yahoogroups.com/
http://www.mail-archive.com/biotech-
news@yahoogroups.com/maillist.html

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] American Stock Exchange Lists Common Stock of Bodisen Biotech Incorporated

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

American Stock Exchange Lists Common Stock of Bodisen Biotech
Incorporated


NEW YORK, Aug. 26 The American Stock Exchange(R) (Amex(R))
today listed the common stock of Bodisen Biotech, Incorporated,
under the ticker symbol BBC.
Bodisen Biotech, Inc. (the "Company" or "Bodisen") is
incorporated in the state of Delaware and is headquartered in the
Shaanxi Province of the People's Republic of China. Bodisen engages
in the business of manufacturing and marketing a brand of organic
fertilizer to the five leading agricultural provinces of China.

"Bodisen joins the growing number of international companies
that have chosen to list on the American Stock Exchange, and we are
pleased to have them," said John McGonegal, senior vice president of
the Amex Equities Group.
"We hope to provide them with the tools necessary to thrive as a
publicly-traded company in today's challenging marketplace."
The company has selected Kellogg Capital as its specialist. For
further
information on BBC and other Amex-listed companies, please visit
http://www.amex.com.

The American Stock Exchange(R) (Amex(R)) is the only primary
exchange that
offers trading across a full range of equities, options and exchange
traded
funds (ETFs), including structured products and HOLDRS(SM). In
addition to
its role as a national equities market, the Amex is the pioneer of
the ETF,
responsible for bringing the first domestic product to market in
1993.
Leading the industry in ETF listings, the Amex lists 165 ETFs to
date. The
Amex is also one of the largest options exchanges in the U.S.,
trading options
on broad-based and sector indexes as well as domestic and foreign
stocks. For
more information, please visit http://www.amex.com.

SOURCE American Stock Exchange
Web Site: http://www.amex.com

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
NIH eases ban on employees owning drug, biotech stock - The Boston Globe
NIH eases ban on employees owning drug, biotech stock - The Boston Globe

NIH eases ban on employees owning drug, biotech stock
By Kevin Freking, Associated Press | August 26, 2005

WASHINGTON -- Officials at the National Institutes of Health said yesterday that rules designed to reduce conflicts of interest at the agency went too far, so they eased a prohibition on owning stock in pharmaceutical and biotechnology companies for thousands of employees.

Article Tools
Printer friendly
E-mail to a friend
Nation RSS feed
Available RSS feeds
Most e-mailed
Reprints/permissions
More:
Globe Nation stories |
Latest national news |
Globe front page |
Boston.com
Sign up for: Globe Headlines e-mail | Breaking News Alerts Under the new regulation, about 200 senior employees as well as their spouses and minor children will be prohibited from owning more than $15,000 worth of such stock. Any holdings above that amount will have to be sold by Jan. 30.

But an interim rule issued in February would have had a much broader impact.

Under that rule, about 6,000 scientists and other high-ranking employees would have been required to sell their stock holdings in such companies entirely. An additional 12,000 employees would have been required to keep such holdings to a maximum of $15,000 in value.


Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Novel lipoplex nanoparticle to be used in 1st human trial treating advanced soli

Novel lipoplex nanoparticle to be used in 1st human trial treating
advanced solid cancer
Washington D.C. -- The first clinical trial of a biologic
nanoparticle designed to give back to cancer patients the tumor-
busting gene they have lost is expected to start in September at
Georgetown University Medical Center.
The phase I clinical study will enroll 20 patients with advanced
solid cancers (including most common tumor types), and is the
culmination of more than a decade of work by a team of researchers
led by Professor Esther H. Chang, Ph.D. at the Lombardi
Comprehensive Cancer Center.

Their research has led to development of a tiny structure --
measuring a millionth of an inch across -- that resembles a virus
particle that can penetrate deeply into the tumor and move
efficiently into cells. The device is a "liposome" -- a microscopic
globule made of lipids -- that is spiked on the outside with
antibody molecules that will seek out, bind to, and then enter
cancer cells including metastases wherever they hide in the body.
These molecules bind to the receptor for transferrin that is present
in high numbers on cancer cells.

Once inside, the nanoparticle, which the researchers call
a "immunolipoplex," will deliver its payload -- the p53 gene whose
protein helps to signal cells to self-destruct when they have the
kind of genetic damage characterized by cancer and by cancer
therapies.

More than half of all cancer patients have cancer cells that have
lost normal functioning of the p53 gene, so-called "guardian of the
genome," and the Georgetown researchers believe that restoring the
gene will improve the tumor-killing ability of traditional
treatments.

"We are excited about the promise this nanoparticle has shown in
animal tumor models, and are anxious to offer it to patients," said
Chang, Professor in the Department of Oncology and Co-director of
the Molecular Targets & Developmental Therapeutics Program at
Georgetown.

The federal Food and Drug Administration granted approval for the
trial to begin in late July. The work is being sponsored by grants
from the National Institutes of Health and private foundations.
Additional support comes from SynerGene Therapeutics, a biotech
research firm with which Chang collaborates.

John Marshall, M.D., Director of Developmental Therapeutics and GI
Oncology at Georgetown, will serve as the trial's principal
investigator.

The researchers believe that immunolipoplex represents an advance
over the viral "vectors" that have been used to deliver gene
therapy, because these liposomes do not produce the kinds of
immunologic response seen when disabled viruses are used to carry
the payload. They also say that the nanoparticle is of a small
uniform size and consistency, and has been proven to work in animals
bearing tumor.

In preclinical research, Chang and long-term research colleague
Kathleen Pirollo, Ph.D. have found that these nanoparticles
substantially improve the tumor-fighting power of both chemotherapy
and radiation therapy. These agents work synergistically with
traditional therapies because the newly restored p53 protein helps
push cancer cells that are now damaged to self-destruct.

"We believe this approach will make it difficult for the cancer
cells to become resistant to therapy," Chang said. "As a result,
cancers treated with these liposomal formulations should be less
likely to recur after therapy is complete."

For example, use of these p53-loaded liposomes in combination with
radiation therapy eliminated prostate and head and neck tumors in
mice, which then survived cancer-free for more than 200 days --
until they all died of old age. Similar promising results were seen
when the nanoparticles were combined with chemotherapy to treat
animal models of melanoma and aggressive breast cancer.

Among the solid tumors approved for testing in the clinical trial
are head and neck, prostate, pancreatic, breast, bladder, colon,
cervical, brain, melanoma, liver and lung cancers.

Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Pharmaceutical/Biotech Marketing Excellence: Leveraging the Sales Force to Drive

Pharmaceutical/Biotech Marketing Excellence: Leveraging the Sales
Force to Drive Re-Packaging, Re-Branding and Re-Launching Success

Winning and developing sales force excitement about a re-launch
product is critical to its success during re-launch. More than 65%
of benchmarked pharmaceutical and biotech organizations find
creating excitement, expanding coverage and enhancing incentives
most effective for placing the re-launched product in their sales
force(s), according to a recent study by pharmaceutical research
firm Best Practices, LLC. To drive sales enthusiasm, executives
involve sales leaders from the field at every stage of planning to
ensure complete understanding of the business case for re-launch.
Obtaining sales force buy-in is a change movement process, but
involvement is a critical lever that can be used to impact overall
buy-in.

Best-Practices' study "Product Re-launch Excellence: Transforming
Lackluster Pharmaceutical Products into Market Success Stories" --
complimentary summary available at www3.best-in-class.com/rr605.ad --
provides insights into how leading companies win the hearts and
minds of their sales organization. For example, poor sales force
training at one company was responsible for a lackluster first
launch. As a result, the brand team is now using a distance
education program, from which the team has seen some positive
results.

In addition to insights into re-launch sales force management, this
study also provides a comprehensive overview of field-proven re-
launch strategies, practices and experiences from 14 leading
pharmaceutical and biotech companies in the following critical
areas:

* Setting Re-launch Strategy -- A leading company needed to cut
the price
to re-launch its lackluster drug. However, the sales
organization was
resistant to the proposed cut due to fears of increased
difficulty in
meeting the sales quota. To win their support, the brand team
made the
case to the sales organization that increased volume of sales
would
easily make up for the lower price.
* Re-defining Product Character -- 95% of surveyed companies find
adjusting core message effective or highly effective for
redefining
brand character and brand story in the marketplace.
* Re-launch Marketing Investment Metrics: Companies essentially
share the
same approach to resource allocation for re-launching: the
majority of
investment -- roughly 75% -- is shared by sales, various
promotional
channels, KOLs and advocacy initiatives.
* Case Studies: Read about what made the re-launches of
Zithromax &
Wellbutrin XL so successful.

The research findings are drawn from surveys and interviews of
executives from leading companies including: Abbott Laboratories,
AstraZeneca, Aventis, Eli Lilly, GlaxoSmithKline, Merck, Novartis,
Pfizer and Roche.

To download a complimentary summary or purchase the full
report, "Product Re-launch Excellence: Transforming Lackluster
Pharmaceutical Products into Market Success Stories," visit
www3.best-in-class.com/rr605.ad .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, a pharmaceutical research and consulting firm,
conducts work based on the principle that organizations can chart a
course to superior economic performance by studying the best
business practices, operating tactics and winning strategies of
world-class organizations.

Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Northeastern University President Richard Freeland To Step Down; Board of Truste

Northeastern University President Richard Freeland To Step Down;
Board of Trustees Chair Praises Freeland's Decade of Leadership

BOSTON--(BUSINESS WIRE)--Aug. 24, 2005--Northeastern University
President Richard M. Freeland has informed the University's Board of
Trustees of his intention to step down at the end of the 2005-06
academic year, which will be the tenth year of his presidency.

Dr. Freeland's tenure as President has been a transformative period
for Northeastern.

When appointed in 1996, President Freeland was charged by the Board
with repositioning Northeastern, moving it from the commuter school
it was viewed as to a university more selective in admissions, more
ambitious in scholarship, and more national in influence. The most
telling symbol of the university's success in accomplishing these
goals has been Northeastern's rise in the annual US News ranking
of "best national colleges." In the last five years, the university
has made steady progress, rising from 150 in 2002 to 115 in 2006.
The 2005 and 2006 scores placed Northeastern in the top tier of the
rankings for the first time in its history. For the fall of 2005,
over 25,000 students applied for just 2800 freshman places.

Freeland expressed pride that Northeastern's transformation has been
accomplished by focusing on the University's core values as
a "student-centered, practice-oriented, and urban" institution. The
University's flagship co-op program has been retooled to emphasize
its contribution to student learning. Engagement with the urban
community has been extended and deepened through partnerships to
build affordable housing in Roxbury, provide health care in
community-based centers, and train teachers for the city's schools.
Attention to student development has continued to be Northeastern's
central focus. The financial aid budget has increased by over 300%
in the last ten years to keep the university accessible to students
of limited financial means.

Freeland has given particular emphasis to establishing Northeastern
as a national leader in "practice-oriented education," an approach
to student development that integrates classroom study with
workplace experience and academic work in the liberal arts and
sciences with studies in professional disciplines. In a 2004 article
in the Atlantic Monthly titled "The Third Way," Freeland argued that
practice-oriented education is achieving recognition as a powerful
alternative to more traditional educational approaches at some of
the nation's leading academic institutions.

During Freeland's years the University's academic, scholarship and
research expertise has grown significantly. The University has made
thirteen appointments of nationally known scholars to named chairs
or distinguished professorships and has achieved growing success as
a center for research, particularly in applied fields. In 2000 the
campus was designated an Engineering Research Center by the National
Science Foundation--one of only twenty two such centers in the
country--to develop and commercialize technology in the fields of
sensing and imaging. Last year Northeastern was one of six
institutions nationally to be selected by NSF as a center for
research in Nanotechnology. A new Center for Drug Discovery is the
keystone of the University's $10 million Biotech Initiative. The
Center for Urban and Regional Policy and the Center for Labor Market
Studies are two of region's most important sources of policy-
oriented scholarship on urban issues. In 2003 the university
launched a five-year, seventy-five million dollar Academic
Investment Plan to expand the faculty by one hundred professors.

"On behalf of the Board of Trustees and the Northeastern University
community I wish to express our tremendous gratitude to President
Freeland for his tireless efforts and unwavering dedication to
Northeastern and to making this University shine in every way," said
Neal F. Finnegan, Chairman of the Board of Trustees. "The physical
and academic transformation of Northeastern that he has overseen has
been nothing short of spectacular in terms of the impact that it has
had on our student body and on the City of Boston."

During Freeland's tenure, the face of the University changed
dramatically. Traditionally characterized by plain, utilitarian
buildings surrounded by acres of parking lots, the campus has been
transformed into an attractive urban oasis. Since 1996, Northeastern
has invested $455 million in new facilities and has built ten
student residence halls, new homes for the colleges of Health
Science and Computer and Information Science, a recreation and
squash facility, and a high rise parking garage, and has created an
entirely new west campus. Much of this was made possible by a
successful $200 million capital campaign. Within the last three
years the university has received three major awards for design
excellence, including the 2005 Harleston Parker Medal from the
Boston Society for Architects who have designated Northestern's new
16-story residential tower as "the most beautiful building in Boston
within the last ten years."

President Freeland commented: "At the time of my appointment I said
that the Northeastern presidency was the best job in American higher
education. That statement holds true today. I have felt truly
blessed to be part of the most constructive and engaged colleague
community I have ever experienced. It has been an honor and a
privilege and I am grateful to all the members of the Northeastern
community that have worked so hard over the past ten years."

Board Chairman Finnegan indicated that the Trustees will be
announcing a selection process to name Freeland's successor within
the next several days. During the year ahead Freeland will work with
the Board to assure a smooth transition. A new president is expected
to be in place by the summer of 2006.

Freeland indicated that he had no definite plans for the
future. "For the moment, I am focused on the challenges of the year
ahead, including further pursuit of our top one hundred goal,
completion of the leadership campaign, and drafting our new physical
master plan." He continued, "I plan to use a sabbatical during 2006-
07 to think about the next phase. It has been a great ten years, but
a decade is about right for the presidency of a major university. It
is time to give someone else a chance to lead this terrific
University. As for me, I'll be 65 next year, so there is time for
another chapter. I am not retiring, but looking forward to the next
challenge."

Northeastern University
Highlights of the Freeland Years

1995 2005

National Ranking (US News and World
Report) 162 (1995 ed.) 115 (2006 ed.)
Endowment $282 (FY96) $558M (FY05)
External Funding $22M (FY96) $46M (FY05)
Applications Received for Freshmen
Admissions 11,800 (fall 95) 25,500 (Fall
05)
Acceptance Rate for Freshmen
Admissions 85% 47%
Average SAT Scores of Entering
Freshmen 1008 1224
Percent of freshmen in Top 10% of
High School Class 16% 36%
Percent of Freshmen from Outside
Massachusetts 49% 66%
Percent Freshman of Color 21% 25%
Freshman to Sophomore Retention
Rate 71% (Fall 95) 88% (Fall 04)
Freshmen Graduating in Six Years 39% (Spring 95) 60% (Spring 05)

Additional Information

-- Level of external funding increased more than 100% in the
last
ten years.

-- 13 appointments of nationally known scholars were made to
named chairs or distinguished professorships.

-- Successfully led a $200 million capital campaign, the largest
in the history of Northeastern.

-- Percentage of students in university housing increased from
33% (fall 95) to 50% (fall 04).

-- New programs and research centers were established including
the New Center for Drug Discovery, which is the keystone of
the University's $10 million Biotech Initiative and the
Center
for Urban and Regional Policy, which has become a cornerstone
of the university's work in public policy.

-- Recognition and awards included the following:

-- In 2002, the campus was designated an Engineering
Research
Center by the National Science Foundation.

-- In 2004, NU was one of six institutions to be selected by
the National Science Foundation as a center for research
in Nanotechnology.

-- Since 2002, NU has received three major awards for design
excellence including the 2005 Harleston Parker Medal from
the Boston Society of Architects.

-- In 2003, the first and only year in which this ranking
was
done by US News, Northeastern ranked #1 in the country
for
universities that connect classroom study and workplace
experience.

About Northeastern

Northeastern University, located in the heart of Boston,
Massachusetts, is a world leader in practice-oriented education and
recognized for its expert faculty and first-rate academic and
research facilities. Northeastern integrates challenging liberal
arts and professional studies with the nation's largest cooperative
education program. Through co-op, Northeastern undergraduates
alternate semesters of full-time study with semesters of paid work
in fields relevant to their professional interests and major, giving
them nearly two years of professional experience upon graduation.
The majority of Northeastern graduates receive a job offer from a co-
op employer. Cited for excellence four years running by U.S. News &
World Report, Northeastern has quickly moved up into the top tier
rankings - an impressive 35 spots in four years. In addition,
Northeastern was named a top college in the 2006 edition of the
Princeton Review's annual "Best Colleges" issue. For more
information, please visit http://www.northeastern.edu.

Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] CeMines Expands Depth of the BioSystems Division Executive Management Team

CeMines Expands Depth of the BioSystems Division Executive
Management Team

Dr. Pauline Gee, Ph.D. Appointed Vice President and General Manager;
Anosheh Amery Appointed Vice President of Sales and Marketing

CeMines, Inc. today announced that Pauline Gee, Ph.D., (52), has
been appointed Vice President and General Manager of the Company's
BioSystems Division. Dr. Gee is responsible for the BioSystems
Division operations, P&L and building the recently announced product
management organization. In addition, CeMines also announced the
appointment of Anosheh Amery, (43), as Vice President of Sales and
Marketing for its BioSystems Division, reporting to Dr. Gee. The
appointments are effective immediately.

Dr. Gee joins CeMines from MDS Pharma Services, a contract drug
discovery company, where she was Vice-President of Predictive
Biology, responsible for directing the company's chemogenomics and
toxicogenomics efforts. Prior to joining MDS Pharma Services, Dr.
Gee was President and CEO of Xenometrix, Inc., a biotech company
pioneering gene expression profiling necessary to describe cellular
regulatory responses to compounds. She earned her doctorate in free
radical chemistry from Simon Fraser University, in British Columbia,
Canada. Her post-doctorate studies focused on analytical chemistry
and constructed Ames strains, which were patented in the
Biochemistry and Molecular Biology Division at the University of
California at Berkeley. Dr. Gee also did post-doctoral work in DNA
repair of neurons in the Biological Sciences Department at Stanford
University. Pauline will report to Roger Attick, CEO of CeMines,
Inc.

Anosheh Amery joins CeMines from Invitrogen, where he was
responsible for directing the launch of more than 15 new products.
He also managed new- business development, where his
responsibilities included the evaluation and strategic planning of
new business opportunities. In this roll Anosheh guided Invitrogen's
entry into the molecular diagnostics market. Prior to Invitrogen,
Mr. Amery was at QIAGEN, where he managed key clinical products for
the diagnostic, pharmaceutical, academia and HLA sectors. He
received a Bachelor of Science degree in Physiological Sciences from
UCLA. He then received an MBA from one of the most prestigious
graduate business schools in Europe, SDA Bocconni in Milan, Italy.

"CeMines has advanced our CellCorrect(TM) product family pre-market
development and clinical studies at a head-spinning pace," said
Roger Attick, CEO of CeMines, Inc. "At this stage of a company's
growth, it is critical to perform an introspective evaluation of
strengths and weaknesses. Our evaluation concluded it was time to
add key expertise and management depth." Mr. Attick then added: "We
are about to begin a substantial transition from R&D and prototypes,
to global commercialization of a novel family of clinical cancer
products. The time is now to adopt more disciplined and rigorous
product management, commercialization 'best-practices,' theranostics
platform R&D, and execute on our partnering strategy as we organize
clinical sales channels, international marketing alliances and
related distribution agreements."

About CeMines, Inc.

CeMines, Inc. is a Life Sciences Systems Biology company,
specializing in cell regulatory network research and molecular
diagnostics R&D that is principal to commercialization of novel
clinical products for worldwide use in diagnosis, treatment and
prevention of cancer. The company was founded in 2000 by Dr. Toomas
Neuman, Ph.D., Dr. Kaia Palm, Ph.D., and Mr. Richard Cavalli.
Company headquarters are located in Golden, Colorado. CeMines'
Diagnostics and Theranostics R&D is located in La Jolla, California,
and the company's European Union-based subsidiary of CeMines
International, CeMines Estonia OU, is located in Tallinn, Estonia.

Forward-Looking Statements

Any statements in this press release about future expectations,
plans or prospects for the company, including the company's
expectations and plans to complete the FDA review and clearance
process and CE Marking in the EU for CellCorrect LAb,
constitute 'Forward-Looking' statements. These statements involve
risks and uncertainties that may cause results to differ materially
from those set forth in these and previous statements. Forward-
looking statements should be evaluated along with other information
released by the company.

Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Greer Adds Prominent Research Immunologist to Research and Development Team

Greer Adds Prominent Research Immunologist to Research and
Development Team

LENOIR, N.C. Aug 24, 2005 - Greer, a leading supplier of allergy
immunotherapy products and treatments, announced the addition of
research immunologist Fabien Lu, M.D., Ph.D. to Greer's Research and
Development Team. Included in Dr. Lu's many responsibilities will be
a primary focus around bringing his expertise to the oromucosal
research program. Prior to joining Greer, Dr. Lu worked in the
Virology and Immunology Unit of the California Regional Primate
Research Center at the University of California in Davis.

Dr. Lu's postgraduate work as a research immunologist has led to a
productive career with numerous peer-reviewed publications. He has
collaborated with scientists at major universities and biotech
companies to develop immunoassays for evaluating antibody and cell-
mediated immune responses. In 2002 Dr. Lu was presented an award by
the University of Alabama at Birmingham for his contributions in
molecular basis of NALT-induced mucosal immunity to SIV. He received
two more awards in 2002 and 2004 for his work studying
immunogenicity of rhesus monkeys.

"We are excited that Dr. Lu has chosen to join the Greer research
team," says Dr. Robert Esch, Greer vice president of research and
development. "With his experience and expertise, Dr. Lu will play an
integral role in expanding our research programs and developing our
second generation allergy immunotherapy products."

Dr. Lu began his career with a residency in medicine at Jilin
Medical University, Jilin, China, in 1985. He attended the Medical
University of Norman Bethune, Changchun, China, in 1987 in the field
of microbiology and infectious diseases. In 1991 Dr. Lu received a
master's degree in immunology and infectious disease from the
Pasteur Institute and University of Paris. He completed his Ph.D. in
1994 in immunology and virology while still attending the Pasteur
Institute.

About Greer

Greer, established in 1904 and located in Lenoir, North Carolina, is
a provider of allergy immunotherapy products and services for
treating humans and animals. Greer's highly skilled scientists
provide technical support for customers by continuing to focus and
improve the lives of allergic patients.

Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech policy to be formulated soon
Biotech policy to be formulated soon (RSSFeedReader)

Biotech policy to be formulated soon
By Staff Reporter
Aug 24, 2005, 12:13

A National Biotechnology Policy draft finalised recently awaits adoption, Science, Information and Communication Technology Minister Dr Abdul Moyeen Khan informed yesterday.

Addressing a conference on 'Biotechnology in Agriculture: Myths and Realities', Dr Khan said a taskforce headed by Prime Minister Begum Khaleda Zia has been formed to consider the policy that he expected to be transparent and easily comprehensible.

"The construction of National Biotechnology Institute to conduct research on latest issues is nearing completion at Savar. All these attempts categorically indicate how much importance the government has attached to this field," the minister said.

The conference jointly organised by the US Embassy in Dhaka and the Bangladesh Agricultural Research Council (BARC) at the Brac Centre in the city called for adoption of biotechnology in the country's agriculture to boost up production and feed the growing population.



Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Drug firm moving to Boca Raton
Drug firm moving to Boca Raton

Drug firm moving to Boca Raton
By Stacey Singer

Palm Beach Post Staff Writer

Wednesday, August 24, 2005

UPDATED: 2:00 p.m. August 24, 2005

A small specialty drug company with offices in Buenos Aires, Argentina is moving its U.S. corporate headquarters from Wilmington, North Carolina to Boca Raton, the state's economic development agency, Enterprise Florida, announced Wednesday morning.

The firm, Osmotica Pharmaceuticals, has already moved seven executives from Wilmington to its new headquarters in the Sanctuary Centre at 4800 North Federal Highway in Boca Raton. Over the next three years, it expects its payroll to grow to about 25, said the company's chief financial officer, Richard E. Martin.

Scripps in South Florida
Post coverage of the biotech facility in Palm Beach County



State Sen. Ron Klein, D-Boca Raton, said the company's choice of Boca Raton showed that technology firms would move throughout the region, not just into the designated biotech parks that have been the focus of so much debate.



Biotech in Arizona Biotech Entrepreneurs
High Tech Arizona Famous Quotes Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Leaders upbeat about progress in Winston-Salem - 2005-08-24
Leaders upbeat about progress in Winston-Salem - 2005-08-24

Bill Dean, president of Idealliance, spoke of development progress at the Piedmont Triad Research Park, where 342,000 square feet of space is already built and an additional 177,000 square feet is nearing completion.

"We are no longer fledgling," he said. "We're emerging. We're positioning ourselves correctly to do great things in Winston-Salem and the Piedmont Triad."

One item that could help biotech growth is that the city is close to finalizing a deal that would bring the N.C. State Biotech Conference to the Twin City next May, said Bob McCoy, president of the Winston-Salem Convention & Visitors Bureau.



Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News
Biotech News
Biotech News


Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News
Biotech News
Biotech News


biotech news
biotech news
biotech news
biotech news
biotech news
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News
Biotech News
Biotech News
Biotech News

Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Bodisen Biotech Announces Record Second Quarter Earnings of $0.17 per Share, 99%

Bodisen Biotech Announces Record Second Quarter Earnings of $0.17
per Share, 99% Increase in Revenue and 48% Increase in Net Income;
Bodisen Provides Earnings Guidance for 2005

NEW YORK Aug. 23, 2005--Bodisen Biotech, Inc. (OTCBB: BBOI, website:
www.bodisen.com) announced financial results for its second quarter
ending June 30, 2005. The following are some of the highlights as
reflected in its filing with the SEC:

Selected Second Quarter 2005 Results Compared to the Same Period in
2004

-- Revenue of $8,416,805, an increase of 99%

-- Net income of $2,692,014, an increase of 48%

-- Gross profit of $3,255,664, an increase of 64%

-- Basic earnings per share of $0.18 (fully diluted:$0.17), an
increase of 50% for basic earnings per share and 42% for fully
diluted

Selected First Half 2005 Results Compared to the Same Period in 2004

-- Revenue of $13,118,480, an increase of 104%

-- Net income of $3,488,746, an increase of 55%

-- Gross profit increased 72% compared to the six month period ended
June 30, 2004

-- Basic earnings per share of $0.23 (fully diluted: $0.22), an
increase of 53% for basic earnings per share and 47% for fully
diluted

REVENUE

Bodisen generated net revenue of $8,416,805 for the three month
period ending June 30, 2005, an increase of $4,186,600, or 99%,
compared to $4,230,205 for the same period in 2004. For the six
months ended June 30, 2005, the company reported net revenues of
$13,118,480 an increase of $6,702,186 or 104% compared to $6,416,294
for the comparable period in 2004. The increase in revenue was
primarily attributable to the completion of a new manufacturing
facility which had a major impact on manufacturing capacity, and a
renewed focus on marketing efforts as the company entered new
territories, resulting in increases in the customer base and related
volume of recurring and new customer sales.

NET INCOME

Bodisen reported net income of $2,692,014 for the three month period
ended June 30, 2005, an increase of $867,999, or 48% from
$1,824,015. For the six months ended June 30, 2005, Bodisen reported
net income of $3,488,746 an increase of $1,243,756 or 55% compared
to $2,244,990 for the comparable period in 2004. The increase was
attributable to the growth in demand for the Company's products as
they entered new markets throughout China.

EARNINGS GUIDANCE FOR YEAR 2005

Bodisen affirmed fiscal 2005 (December yearend) guidance for
earnings of approximately $8 million (including 1Q05 one time
financing related charge), or approximately 50 cents per share, on
revenue of approximately $28 million. Guidance does not include
positive impact from increased sales channels and further expansion
of manufacturing capacities, as a result of the Company's planned
dual listing before yearend on the AIM market of the London Stock
Exchange raising up to 10 million British Pound (US$18 million)
through placement of new shares (Broker: UK investment bank Charles
Stanley; Reporting accountant: Deloitte & Touche).

MANAGEMENT COMMENTS

Ms. Qiong Wang, Chairman and CEO of Bodisen commented: "We are
pleased that our second quarter results have exceeded our
expectations. Our new production facility has allowed us to meet
strong demand for our environmentally friendly organic fertilizer
products. The rapidly growing Chinese economy has lifted the
standard of living for 1.3 billion Chinese, including 900 million
farmers. Chinese consumers are very conscious of food quality. Many
Chinese only use foods and vegetables that are grown with organic
fertilizers although such foods are slightly higher priced. In order
to increase their household income, farmers across China demand
fertilizers that not only generate higher crop yields, but also are
organic and environmentally friendly. The year of 2005 should be
another banner year of strong earnings growth for Bodisen."

Ms. Wang continued her comment: "During the second half of 2005, in
addition to our continued focus on core business, Bodisen's
management is committed to increasing shareholder awareness. We look
forward to presenting Bodisen to US and European fund managers
through road shows in the fall."

About Bodisen Biotech, Inc.

Utilizing proprietary technologies, Bodisen sells over 60 packaged
products in 3 product categories: Organic Compound Fertilizer;
Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's
organic fertilizers can be absorbed by plants within 48 hours while
enriching soil conditions without the damaging effects associated
with chemical fertilizers.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of
China and the economic gateway to the western regions of China. The
Bodisen brand is a highly recognized fertilizer brand in China. Its
environmentally friendly "green" products support the mandate of the
Chinese government to increase crop yields for the purpose of
decreasing China's dependency on food imports. Among China's
population of 1.3 billion, approximately 900 million Chinese are
farmers whose income depend on their crop yields.

Safe Harbor Statement

This press release may contain forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on the
current expectations or beliefs of Bodisen Biotech, Inc. management
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Nabi Biopharmaceuticals Appoints Leslie Hudson, Ph.D., to its Board of Directors

Nabi Biopharmaceuticals Appoints Leslie Hudson, Ph.D., to its Board
of Directors


- Pharmaceutical Executive Brings Scientific and Commercial
Experience to
Nabi Biopharmaceuticals' Board -

Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has
elected Leslie Hudson, Ph.D., to its board of directors. Dr. Hudson
is currently president and chief executive officer of DOV
Pharmaceutical, Inc., and has served in several senior management
positions, including vice president of discovery research at Glaxo
Wellcome, group vice president and general manager at Phamacia Corp.
and executive vice president and chief operating officer at Repligen
Corp. With the addition of Dr. Hudson, Nabi Biopharmaceuticals'
board now totals eight members.

"Les brings a broad research background and commercial
experience in Europe and the United States that will be a tremendous
asset to our board of directors and company," stated Thomas H.
McLain, chairman, chief executive officer and president, Nabi
Biopharmaceuticals. "For more than 30 years, Les has held a number
of strategically important positions within the biotechnology and
pharmaceutical industries and in academia. We will benefit from his
expertise and experience in discovery research, product development
and commercialization at this significant point in Nabi
Biopharmaceuticals' strategic transformation."
Prior to DOV Pharmaceuticals, Dr. Hudson served as vice provost
for Strategic Initiatives at the University of Pennsylvania, where
he facilitated corporate partnerships and was responsible for
technology transfer and commercialization, corporate research and
development collaborations and regional economic development. Prior
to this position, he served in several positions at Pharmacia,
including senior vice president of research and exploratory
development, and senior vice president of emerging technology and
commercial development. He was also general manager and group vice
president of ophthalmology, where he was responsible for the
company's $1 billion ophthalmology business including the launches
of Xalatan, XalEase, Tecnis and Xalacom. Dr. Hudson also worked at
Glaxo in several senior research positions including head of cancer,
metabolic and hyperproliferative disease and vice president for
discovery research, in which he headed the company's genomics
program.
In addition to these corporate positions, Dr. Hudson has also
worked in
academia. He was a visiting scientist in the department of cell
biology at
Harvard University and head of the Department of Immunology at St.
George's
Hospital Medical School in London, where he taught for 12 years.
Dr. Hudson received his Ph.D. in immunology from the Imperial
College and
Mi